Skip to main content
Equibles
NTRA logo

NTRA · Natera, Inc.

Track NTRA — free

Use NTRA with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about NTRA

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$309.93 -0.85 (-0.27%) At close · Aug 14
Market Cap
$44.67B
Shares
144.14M

Natera, Inc. Earnings Call Transcripts

Every quarterly earnings call for Natera, Inc. (NTRA) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▲33.2% $210.64M −$121.48M '22 Q3 22-11-08 ▲25.6% $217.25M −$142.57M '22 Q4 23-02-28 ▲24.5% $241.76M −$136.94M '23 Q1 23-05-09 ▲31.9% $261.40M −$110.80M '23 Q2 23-08-03 ▲27.4% $268.31M −$109.03M '23 Q3 23-11-08 ▲43.2% $311.11M −$78.03M '23 Q4 24-02-28 ▲52.1% $367.74M −$67.60M '24 Q1 24-05-09 ▲58.1% $413.35M −$37.46M '24 Q2 24-08-08 ▲63.9% $439.76M −$31.59M '24 Q3 24-11-12 ▲53% $476.06M −$53.77M '24 Q4 25-02-27 ▲36.5% $501.83M −$66.94M '25 Q1 25-05-08 ▲32.2% $546.60M −$100.94M '25 Q2 25-08-07 ▲34.7% $592.18M −$87.54M '25 Q3 25-11-06 ▲39.8% $665.50M $47.26M '25 Q4 26-02-26 ▲38.8% $696.64M −$85.09M '26 Q1 26-05-07 LATEST ▲37.7% $752.75M −$66.97M '26 Q2 26-08-06
Conference
Investor event
2026-08-12
Canaccord Genuity 46th Annual Growth Conference
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-08-06
Natera, Inc. Q2 Earnings Conference Call
Confident tone Signatera Oncology Momentum Gross Margin and COGS International Expansion (Japan)
Revenue
$752.75M
▲ 37.7% YoY
Diluted EPS
$-0.47
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-06-08
Goldman Sachs 47th Annual Global Healthcare Conference
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-07
Natera, Inc. Q1 FY2026 Earnings Call
Confident tone Oncology / Signatera MRD Growth Reimbursement and Prior Authorization Fetal Focus Product Launch (Women's Health)
Revenue
$696.64M
▲ 38.8% YoY
Diluted EPS
$-0.60
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-02-26
Natera, Inc. Q4 FY2025 Earnings Call
Confident tone Revenue Growth and 2026 Guidance MRD Volume and Adoption Gross Margin Expansion
Revenue
$665.50M*
▲ 39.8% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-06
Natera, Inc. Q3 FY2025 Earnings Call
Confident tone Signatera MRD growth and momentum Gross margin expansion and ASP improvement Revenue and 2025 financial guidance raise
Revenue
$592.18M
▲ 34.7% YoY
Diluted EPS
$-0.64
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
Natera, Inc. Q2 FY2025 Earnings Call
Confident tone Signatera oncology volume growth Gross margin expansion Medicare reimbursement expansion for noncovered indications
Revenue
$546.60M
▲ 32.2% YoY
Diluted EPS
$-0.74
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-08
Natera, Inc. Q1 FY2025 Earnings Call
Confident tone Signatera oncology growth Gross margin expansion Clinical data and study readouts
Revenue
$501.83M
▲ 36.5% YoY
Diluted EPS
$-0.50
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-02-27
Natera, Inc. Q4 FY2024 Earnings Call
Confident tone Signatera oncology growth Gross margin and COGS progress 2025 guidance and execution risk
Revenue
$476.06M*
▲ 53% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-12
Natera, Inc. Q3 FY2024 Earnings Call
Confident tone Signatera oncology volumes Reimbursement and ASP improvement Women's health and Invitae integration
Revenue
$439.76M
▲ 63.9% YoY
Diluted EPS
$-0.26
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-08
Natera, Inc. Q2 FY2024 Earnings Call
Confident tone Signatera Oncology Revenue Growth and Guidance Raise ALTAIR Trial Delay
Revenue
$413.35M
▲ 58.1% YoY
Diluted EPS
$-0.30
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-09
Natera, Inc. Q1 FY2024 Earnings Call
Confident tone Signatera / Oncology Performance Gross Margin Expansion Women's Health Momentum
Revenue
$367.74M
▲ 52.1% YoY
Diluted EPS
$-0.56
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-02-28
Natera, Inc. Q4 FY2023 Earnings Call
Confident tone Revenue and Volume Growth Oncology / Signatera Women's Health and Invitae Acquisition
Revenue
$311.11M*
▲ 43.2% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-08
Natera, Inc. Q3 FY2023 Earnings Call
Revenue
$268.31M
▲ 27.4% YoY
Diluted EPS
$-0.95
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-03
Natera, Inc. Q2 FY2023 Earnings Call
Revenue
$261.40M
▲ 31.9% YoY
Diluted EPS
$-0.97
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-09
Natera, Inc. Q1 FY2023 Earnings Call
Revenue
$241.76M
▲ 24.5% YoY
Diluted EPS
$-1.23
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-02-28
Natera, Inc. Q4 FY2022 Earnings Call
Revenue
$217.25M*
▲ 25.6% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-08
Natera, Inc. Q3 FY2022 Earnings Call
Revenue
$210.64M
▲ 33.2% YoY
Diluted EPS
$-1.25
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
Natera, Inc. Q2 FY2022 Earnings Call
Revenue
$198.20M
▲ 39.6% YoY
Diluted EPS
$-1.50
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-05
Natera, Inc. Q1 FY2022 Earnings Call
Revenue
$194.13M
▲ 27.5% YoY
Diluted EPS
$-1.45
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-02-24
Natera, Inc. Q4 FY2021 Earnings Call
Revenue
$173.03M*
▲ 54% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-04
Natera, Inc. Q3 FY2021 Earnings Call
Revenue
$158.12M
▲ 61.1% YoY
Diluted EPS
$-1.63
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-05
Natera, Inc. Q2 FY2021 Earnings Call
Revenue
$142.03M
▲ 64.2% YoY
Diluted EPS
$-1.32
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-06
Natera, Inc. Q1 FY2021 Earnings Call
Revenue
$152.32M
▲ 62% YoY
Diluted EPS
$-0.74
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-02-25
Natera, Inc. Q4 FY2020 Earnings Call
Revenue
$112.38M*
▲ 35% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-05
Natera, Inc. Q3 FY2020 Earnings Call
Revenue
$98.14M
▲ 26% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-08-05
Natera, Inc. Q2 FY2020 Earnings Call
Revenue
$86.47M
▲ 16.3% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-06
Natera, Inc. Q1 FY2020 Earnings Call
Revenue
$94.01M
▲ 40.7% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-02-26
Natera, Inc. Q4 FY2019 Earnings Call
Revenue
$83.24M
▲ 24.3% YoY
Diluted EPS
$-0.46
Gross margin
46.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Showing 1–29 of 29 earnings calls
Key facts CIK 1604821 CUSIP 632307104 13F (30d) 787 filings 762 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)